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Abstract
Multi-vessel coronary artery disease is quite a common state, which is often diagnosed by coronary angiography
in patients with both stable coronary artery disease and acute coronary syndromes. Major difficulties in
percutaneous coronary intervention include stent thrombosis and the need for antiplatelet therapy (aspirin and
a P2Y12 inhibitor). Stent thrombosis leads to the recurrence of myocardial infarction and may occur within the
first few hours after percutaneous coronary intervention. The use of dual antiplatelet therapy, especially that
combined with low-molecular-weight heparin in the first days after myocardial infarction, poses a risk of bleeding,
which often occurs in real clinical practice. Among P2Y12 inhibitors, ticagrelor causes bleeding somewhat
more frequently than clopidogrel. A case of multi-vessel coronary artery disease is described in this paper.
Coronary angiography revealed right-dominant circulation; occlusion of the proximal and medial segments of
the right coronary artery, thrombolysis in myocardial infarction flow grade 0; stenosis of the left main coronary
artery (50-60%), thrombolysis in myocardial infarction flow grade 2; diffuse stenosis of the medial and distal
segments of the left anterior descending artery, thrombolysis in myocardial infarction flow grade 1; stenosis of
the proximal segment of the left circumflex artery (> 75%), thrombolysis in myocardial infarction flow grade 1.
The patient underwent percutaneous coronary intervention; the stents were implanted in the infarct-dependent
right coronary artery. The clinical course was complicated by early stent thrombosis with subsequent thrombus
extraction; a day later melena developed. Bleeding was stopped, the intensity of antithrombotic therapy was
reduced: the combination of aspirin and ticagrelor was replaced by the combination of aspirin and clopidogrel.
Six weeks after stenting of the infarct-dependent coronary artery, complete myocardial revascularization (hybrid
intervention) was performed: coronary artery bypass grafting [the left internal mammary artery→ the left anterior
descending artery], coronary autogenous bypass grafting [the aorta→ the right coronary artery and the aorta→
the left circumflex artery]. The role of fractional flow reserve or instantaneous wave-free ratio-controlled complete
myocardial revascularization techniques is discussed. The following algorithm for myocardial revascularization
was used: percutaneous coronary intervention for the right coronary artery + coronary artery bypass grafting-3:
the left internal mammary artery → the left anterior descending artery, the aorta → the left circumflex artery,
the aorta→ the right coronary artery.
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Background
Multi-vessel coronary artery disease (MVCAD) is observed
in 30-60% of cases of acute ST-segment elevation myocar-
dial infarction (STEMI) [1]. Coronary artery bypass grafting
(CABG) in patients with MVCAD makes it possible to achieve
complete revascularization, which prevents angina attacks, im-
proves the quality of life, increases exercise tolerance [1, 2].
However, advanced age, left ventricular dysfunction, acute
heart failure (AHF), cardiogenic shock, and comorbidity worsen
the prognosis in patients undergoing CABG [2–4]. Both mini-
invasive CABG revascularization technique [3, 4] and hy-
brid reperfusion using percutaneous coronary intervention
(PCI) with stent implantation in the infarct-dependent coro-
nary artery (IDCA) and coronary artery bypass grafting of
remaining arteries with stenoses of more than 50% [2] were
important steps in cardiac surgery. The variant of complete
myocardial revascularization along with stent implantation
in all the coronary arteries with hemodynamically significant
stenoses is widely discussed [5–7]. The efficiency of this
strategy increases with the use of FFR-controlled revascu-
larization [9, 12]. This technique requires the study of the
so-called fractional flow reserve (FFR), that is the ratio of
a coronary artery pressure proximal and distal to stenosis
(normal value is > 0.80). This technique requires the mea-
surement of coronary pressure under conditions of maximum
vasodilation, which is achieved by intravenous adenosine. A
modified version of this ratio is the criterion of the instanta-
neous wave-free ratio (iFR) that is a transcoronary gradient
during the diastolic wave-free period. The iFR technology
determines the level of pressure distal to the stenosis (Pd)
and in the aorta (Pa) - Fig. 1. The method of determining
the iFR does not require the use of vasodilators; it is simple,
safe, and cheap. For the iFR, the criterion for deciding about
expediency of stent implantation in all the coronary arteries
with intermediate grade stenosis (40-90%) is the value of 0.89
(Fig. 2). If the value of the FFR is > 0.80, or the iFR is > 0.89,
stent implantation in the coronary artery with such stenosis
is not appropriate and can be delayed, and if the value of the
FFR is < 0.80, or the iFR is < 0.89, PCI is appropriate.
Therefore, iFR-controlled stent implantation is recom-
mended for stenoses with narrowing of the lumen at the range
of 40-90% and the values of the iFR < 0.89, or FFR < 0.80.
The Fractional Flow Reserve Versus Angiography for Mul-
tivessel Evaluation 2 (FAME2) study confirmed better effi-
cacy of FFR (iFR) -guided PCI as compared to only optimal
medical treatment (OMT) (hazard ratio (HR) 0.32 [95% confi-
dence interval (CI) 0.19-0.53; p < 0.001]) [9–11]. In Ukraine,
FFR/iFR-guided PCI is performed in the Institute of Car-
diology named after Academician M.D. Strazhesko of the
National Academy of Medical Sciences Of Ukraine, Heart In-
stitute of the Ministry of Health of Ukraine, National Institute
of Cardiovascular Surgery named after M.M. Amosov of the
National Academy of Medical Sciences of Ukraine. There is
a reason to believe such a method will soon be used in all the
reperfusion centers of Ukraine.
Figure 1. IFR measurement.
Adopted from Berry C et al. [13]
Figure 2. Reference range of the iFR and FFR.
Adopted from Davies JE et al. [14].
The paper presents an example of two-stage myocardial
revascularization in STEMI with MVCAD and complication
after the first stage – PCI (without the use of FFR/iFR-guided
stent implantation).
Case Report
A 76-year-old man P. was admitted with complaints of very
intense squeezing pain behind and to the left of the sternum
with irradiation to the lower jaw and the left scapular area,
which had appeared suddenly, lasted more than an hour, was
accompanied by shortness of breath, palpitations, cold sweat-
ing, fatigue. Pulse rate was 118 bpm with weak filling; blood
pressure was 110/80 mm Hg (his usual blood pressure was
at the range of 160-170/90-100 mm Hg); heart sounds were
weakened, there was protodiastolic gallop rhythm. There were
auscultated moist rales (> 50% of the lung area; AHF (Killip
class III/ Forrester class IV)). An electrocardiogram (ECG)
revealed sinus rhythm, left axis deviation; QS-pattern with
ST-segment elevation (J-I 0.08 s = 2.5-3.0 mm) in leads II,
III, aVF, V1-V4; qrS-pattern with an elevation of segment
ST (J-I 0.08 s = 2 mm) in leads V5-V6. Some previous ECGs
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revealed atrial fibrillation.
ECG report: ischemic myocardial injury with transmural
necrosis in areas supplied by the right coronary artery (RCA)
and the left main coronary artery (LMA).
Laboratory tests revealed high cardiac troponin I
(125 ng/ml), leukocytosis (27.4×106/ml), hyperuricemia
(670 µ mol/l), high creatinine level (110.0 µ mol/l).
Coronary angiography revealed right-dominant circula-
tion; occlusion of the proximal and mid RCA, thrombol-
ysis in myocardial infarction (TIMI) flow grade 0; steno-
sis of the LMA (50-60%), TIMI-2; diffuse stenosis of the
medial and distal segments of the left anterior descending
artery (LAD) (75-90%), TIMI-1; stenosis of the proximal left
circumflex artery (LCx) (> 75%), TIMI-1.
Heart Team decision: a 76-year-old patient P. needs sur-
gical revascularization (CABG), but due to the impossibility
of performing CABG urgently and AHF (Killip class III/
Forrester class IV) development, hybrid intervention, namely
primary PCI and elective CABG (in 6 weeks) is recommended.
Periprocedural support included aspirin – 300 mg, ticagrelor –
180 mg, unfractionated heparin – 5000 IU.
PCI protocol: two Terumo bare-metal stents (BMS)
(3.0×23.0 mm and 3.0×15.0 mm) were implanted in the
proximal and mid RCA (stent-by-stent technique); control
angiography showed complete restoration of the blood flow
in the RCA (Fig. 3).
Figure 3. Primary PCI performed in patient P.: a) proximal
RCA occlusion, TIMI-0; b) blood flow restoration, TIMI-3.
One hour after the procedure, the patient’s condition sud-
denly deteriorated: chest pain and cold sweating resumed;
elevation of the ST segment in leads II, III, aVF (4 mm)
increased (Fig. 4). Control coronary angiography revealed
thrombosis of the implanted stents and dissection of the mid
RCA.
The extraction of thrombotic masses from the lumen of
the stents in the proximal and mid RCA and optimization
of the implanted stents were performed; the blood flow was
restored with the result of TIMI-3. Dual antiplatelet therapy
(DAPT) including aspirin 100 mg/d and ticagrelor 180 mg/d;
anticoagulants – enoxaparin at a dose of 1 mg/kg twice a day;
nitrates – isosorbide mononitrate 20 mg twice a day were
prescribed to the patient.
Within the day after PCI, the patient’s condition was satis-
factory; however, next morning, after defecation, melena was
noted, that resulted in discontinuing DAPT and performing
esophagogastroduodenoscopy. In the cardiac region of the
stomach, bleeding ulcer was found (there was no reference to
gastric ulcer in the patient’s medical history); Mallory-Weiss
syndrome was diagnosed. Active hemostatic therapy was
started, which proved to be effective. De-escalation of DAPT
was performed: clopidogrel at a dose of 75 mg/d was pre-
scribed instead of ticagrelor at a dose of 180 mg/d. Drug ther-
apy was supplemented with rosuvastatin (20 mg/d), bisopro-
lol (2.5 mg/d), ramipril (2.5 mg→ 5.0 mg/d), corvitin (500 mg
in 50 ml of 0.9% NaCl solution intravenously) and pantopra-
zole (40 mg/d).
Subsequently, the rehabilitation period (the first and the
second stages) was uneventful.
Laboratory findings.
Complete blood count:
- hemoglobin (Hb) – 128 g/l;
- erythrocytes 4.04 T/l;
- color index 0.95;
- platelets 274×109/l;
- erythrocyte sedimentation rate (ESR) 16 mm/h;
- leukocytes 9.7×109/l, including bands – 8%, segmented
neutrophils – 72%, lymphocytes – 25%, monocytes –
3%, eosinophils – 2%.
Biochemical analysis of blood:
- total protein – 74.4 g/l;
- creatinine – 122.2 µ mol/l;
- aspartate aminotransferase (AST) – 58.8 IU;
- alanine aminotransferase (ALT) – 91.7 IU;
- total bilirubin - 15.1 µ mol/l;
- potassium – 4.99 mmol/l;
- sodium – 137.3 mmol/l;
- calcium – 1.8 mmol/l;
- chlorine – 103.3 mmol/l.
Lipid profile:
- total cholesterol – 3.8 mmol/l;
- triacylglycerols – 1.33 mmol/l;
- high-density lipoprotein (HDL) – 1.8 mmol/l;
- low-density lipoprotein (LDL) – 1.39 mmol/l;
- very-low-density lipoprotein (VLDL) – 0.6 mmol/l.
Coagulogram:
- the prothrombin index (PTI) – 83.0%;
- the activated partial thromboplastin time (APTT) – 90.3s;
- the international normalization ratio (INR) – 1.23;
- fibrinogen – 2.64 g/l;
- hematocrit (Ht) – 0.44.
Urine analysis: there were observed normal values.
Echocardiography:
aorta – 2.4 cm, aortic valve leaflets were thickened, the max-
imal pressure gradient was 13.2 mm Hg; the left atrium –
3.9 cm; mitral valve – M-type opening, fibrosis of the leaflets;
the ratio between E-wave and A-wave (E/A ratio) – 0.97;
end-diastolic left ventricular diameter (EDLVD) – 5.6 cm,
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Figure 4. Repeated coronary angiography in patient P.: a) proximal RCA reocclusion, TIMI-0; b) dissection of the mid RCA;
c) RCA after stent optimization, TIMI-3.
end-systolic left ventricular diameter (ESLVD) – 4.3 cm, end-
diastolic left ventricular volume (EDLVV) – 154 ml, end-
systolic left ventricular volume (ESLVV) – 82.0 ml, left ven-
tricular ejection fraction (LVEF) – 47%; hypokinesia of the
inferior wall of the LV and ventricular septum (VS), the thick-
ness of the VS – 1.3 cm in diastole, 1.4 cm in systole (systolic
thickening - 0.1 cm), the thickness of the left ventricular free
wall (LVFW) in diastole – 0.90 cm, in systole – 0.95 cm (sys-
tolic thickening - 0.05 cm), the relative wall thickness of the
LV – 0.39 cm (eccentric LV hypertrophy); right ventricular
diameter (RVD) – 3.2 cm, the systolic pressure in the pul-
monary artery – 37 mm Hg; separation of pericardial layers –
4-5 mm.
Conclusions:
Fibrosis of the atrioventricular (AV) and mitral valves (MV);
LV diastolic dysfunction, type I; eccentric LV hypertrophy;
hypokinesia of the inferior wall and anterior-septal and apical
segments of the LV, the wall motion score index (WMSI) =
1.75, LVEFWMSI- 47.5% (mid-range).
The risk of the fatal cardiovascular event within the fol-
lowing 10 years based on the Systematic Coronary Risk Eval-
uation (SCORE) and atherosclerotic cardiovascular disease
(ASCVD) risk scales was found to be 27% and 19.9%, respec-
tively. The risk of thrombosis on the CHA2DS2-VASc scale
was 5 points (high), the risk of hemorrhagic complications on
the PRECISE-DAPT scale > 25 points (high). The duration
of DAPT was limited up to 1 month due to the high risk of
hemorrhagic complications.
After 6 weeks, the patient was admitted to the second stage
of revascularization and underwent CABG: the left internal
mammary artery (LIMA)→ the LAD, the aorta→ the LCx,
the aorta→ the RCA.
The postoperative period was uneventful.
Clinical diagnosis:
Coronary artery disease: acute transmural STEMI of the infe-
rior, anterior-septal, and apical segments of the LV (circular),
AHF (Killip class III/Forrester class IV) (14.03.2017). Ur-
gent coronary angiography (14.03.2017): occlusion (100%)
of the proximal RCA, TIMI-0; stenosis (50-60%) of the LMA,
TIMI-2; diffuse stenosis of the LAD, TIMI-1; stenosis of the
proximal LCx, TIMI-1.
Ad hoc stenting (14.03.2017) of the proximal and me-
dial RCA with BMS stents (3.0x23.0 mm and 3.0x15.0 mm),
TIMI-3; early stent thrombosis, TIMI-0, dissection of the me-
dial segment of the RCA; thrombextraction, optimization of
the implanted stents, TIMI-3.
Complications:
Bleeding ulcer of the cardiac region of stomach, Mallory-
Weiss syndrome were treated pharmacologically (15.03.2017).
CABG3: the LIMA→ the LAD, the aorta→ the RCA, the
aorta→ the LCx (26.04.2017).
Cardiosclerosis (diffuse and postinfarction). Atrial fibrilla-
tion, paroxysmal form, the European Heart Rhythm Associa-
tion (EHRA) score - IIb, the CHA2DS2-VASc score – 5 points,
the PRECISE-DAPT score > 25 points. Stage IIA chronic
heart failure according to the classification of V.H. Vasylenko-
M.D. Strazhesko, stage C according to the American Col-
lege of Cardiology/American Heart Association (ACC/AHA)
Guidelines, H3L2M2, mid-range LVEF, functional
class (FC) III according to the New York Heart Association
(NYHA).
Concomitant diseases: stage III, grade 2, risk 4 (very high)
arterial hypertension; asymptomatic hyperuricemia.
In this clinical case, on the background of atheroscle-
rotic lesions of all the coronary arteries, acute transmural
STEMI of the inferior and anteroseptal and lateral segments
of the LV (circular) developed; it was complicated by AHF
(Killip class III/ Forrester class IV), early thrombosis of the
implanted stents, dissection in the mid RCA (corrected by
the extraction of the thrombus from the implanted stents and
re-optimization of the stents), gastric bleeding.
Due to the complicated course of STEMI, Heart Team
decided to postpone surgical revascularization for 6 weeks
after urgent PCI (stent implantation in the RCA).
Hybrid revascularization using PCI with stent implan-
tation in the infarct-dependent RCA and delayed complete
surgical revascularization were performed according to the
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European Society of Cardiology/the European Association for
Cardio-Thoracic Surgery (ESC/EACTS) guidelines [5].
An ongoing research and experience exchange regarding
complete revascularization by FFR- or iFR-guided PCI are
being conducted now [6–12].
The best options for hybrid interventions are CABG LIMA
→ LAD + non-LAD PCI with simultaneous or sequential
PCI with stent implantation in the arteries with intermedi-
ate stenoses, CABG LIMA→ LAD, and then PCI non-LAD
arteries that supply blood to other areas of the ischemic my-
ocardium and the variant of MIDCABG → LIMA + PCI
non-LAD. It is also possible to use the scheme CABG2 + PCI
LAD, or MIDCABG2 + PCI LAD [2, 3].
In the presented case, the algorithm for complete revas-
cularization was as follows: PCI RCA + CABG3: LIMA→
LAD, Ao→ LCx, Ao→ RCA (Fig. 5).
Figure 5. Scheme of myocardial revascularization
performed.
CABG3: LIMA→LAD, Ao→LCx, Ao→RCA
Ao – aorta.
Conclusions
1. In the coexistence of MVCAD and STEMI and in the
absence of the possibility of FFR- or iFR-guided PCI
with complete myocardial revascularization, the strat-
egy of choice should be primary PCI with stent implan-
tation in the infarction-dependent artery and subsequent
CABG with complete myocardial revascularization (hy-
brid revascularization).
2. Early complications of PCI (stent thrombosis, coronary
artery dissection, gastrointestinal bleeding) are reasons
for delaying the next stage of CABG; however, they are
not an obstacle for performing complete reperfusion.
3. Complete revascularization in complicated PCI should
be performed not later than 8 weeks after the opening
of the infarction-dependent coronary artery using PCI.
4. Complete myocardial revascularization with PCI RCA
+ CABG3: LIMA→ LAD, Ao→ LCx, Ao→ RCA
may be the strategy of choice for patients with a di-
agnosis of STEMI urgently admitted to a reperfusion
center without the possibility of emergency surgical
revascularization within the first 12-24 hours.
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